NCT00074087View on ClinicalTrials.gov

Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2010

Conditions
Lymphoma
Interventions
DRUG

pegylated liposomal doxorubicin hydrochloride

Trial Locations (11)

10126

Universita di Torino, Turin

31096

Rambam Medical Center, Haifa

A-8010

Karl-Franzens-University Graz, Graz

A-1090

Allgemeines Krankenhaus - Universitatskliniken, Vienna

D-45122

Universitaetsklinikum Essen, Essen

D-07740

Klinikum der Friedrich-Schiller Universitaet Jena, Jena

D-68135

Klinikum der Stadt Mannheim, Mannheim

D-32423

Klinikum Minden, Minden

D-97080

Julius Maximilians Universitaet Hospital, Würzburg

CH-8091

UniversitaetsSpital Zuerich, Zurich

SE1 9RT

St. Thomas' Hospital, London

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00074087 - Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides | Biotech Hunter | Biotech Hunter